ReviewHuman vaccines & immunotherapeutics2012
Importance of circulating antibodies in protection against meningococcal disease.
Review in Human vaccines & immunotherapeutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Systematic review of invasive meningococcal disease epidemiology in the Eastern Mediterranean and North Africa region.BMC infectious diseases · 2021Pooled it
- Sustained salivary IgG but short-lived IgA responses following primary and booster MenACWY-TT vaccination in older adults.Human vaccines & immunotherapeutics · 2026Trial
- Podcast: Immune Persistence After Primary Vaccination with MenQuadfi.Infectious diseases and therapy · 2026Review
- Policies for the immunization against serogroup B meningococcus for adolescents immunized during the first two years of life: A mini review.Human vaccines & immunotherapeutics · 2024Review
- Real-world impact and effectiveness of MenACWY-TT.Human vaccines & immunotherapeutics · 2023Review
- Different Long-Term Duration of Seroprotection againstVaccines · 2020Article
- Limited Neonatal Carbohydrate-Specific Antibody Repertoire Consecutive to Partial Prenatal Transfer of Maternal Antibodies.Frontiers in immunology · 2020Article
- Use of saliva to monitor meningococcal vaccine responses: proposing a threshold in saliva as surrogate of protection.BMC medical research methodology · 2019Article
- Study of the Immune Response in the Elderly: Is It Necessary to Develop a Vaccine againstJournal of aging research · 2019Review
- Challenges and opportunities for meningococcal vaccination in the developing world.Human vaccines & immunotherapeutics · 2018Review
- Four-year antibody persistence and response to a booster dose of a pentavalent MenABCWY vaccine administered to healthy adolescents and young adults.Human vaccines & immunotherapeutics · 2018Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neisseria meningitidis infection results in life-threatening illnesses, including bacteremia, sepsis and meningitis. Early diagnosis and treatment are a challenge due to rapid disease progression, resulting in high mortality and morbidity in survivors. Disease can occur in healthy individuals, however, risk of infection is higher in patients with certain risk factors. N meningitidis carriage and case-fatality rates are high in adolescents and young adults. The absolute incidence of meningococcal disease has decreased partially due to increasing meningococcal vaccination rates. Maintaining protective levels of circulating antibodies by vaccination is necessary for clinical protection against disease. The Centers for Disease Control and Prevention Advisory Committee on Immunization Practices guidelines recommend vaccination for all individuals aged 11 through 12 years, followed by a booster dose at age 16 years for maintenance of protective antibody levels throughout the high-risk years. Despite these guidelines, many adolescents remain unvaccinated and susceptible to infection and disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.